The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers

Clinical and Experimental Pharmacology & Physiology
Chunguo CuiZecheng Yang

Abstract

Cancer immunotherapy has been increasingly applied in the treatment of advanced malignancies. Consequently, immune checkpoints have become a major concern. As PD-1 is an important immunomodulatory protein, the blockade of PD-1 and its ligand PD-L1 is a promising tumour immunotherapy for human carcinoma. In this review, we first discuss the role of the PD-1/PD-L1 interaction in gastrointestinal tract cancers. Targeting PD-1 and PD-L1 in immune cells and tumour cells may show remarkable efficiency in gastrointestinal tract cancers. Second, the PD-1/PD-L1-associated signalling pathway involved in cancer immunotherapy in gastrointestinal tract cancers is discussed. Most importantly, this review summarizes the PD-1/PD-L1-targeted immunotherapy combinations with relevant signalling pathways, which may result in a breakthrough for the treatment of gastrointestinal tract cancers, such as gastric cancer, colorectal cancer and liver cancer. Meanwhile, the review provides a deeper insight into the mechanism of checkpoint blockade immunotherapies.

References

Feb 1, 1984·Japanese Journal of Medicine·T Sakita
Dec 11, 1999·Carcinogenesis·C T Stadtländer, J W Waterbor
Jan 19, 2005·World Journal of Gastroenterology : WJG·Bing LuoPeng Zhao
Apr 9, 2005·Arthritis and Rheumatism·Eric Kai-Pang KongYu-Lung Lau
Mar 1, 2008·The Lancet Oncology·Wai K LeungUNKNOWN Asia Pacific Working Group on Gastric Cancer
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary L Disis
Jul 28, 2010·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Ji ChenGui-Qiang Wang
May 10, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·James KrempskiKeith L Knutson
Jan 13, 2012·Current Opinion in Immunology·Suzanne L TopalianDrew M Pardoll
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Dec 10, 2013·Journal of Leukocyte Biology·Seong Jeong ParkYoung Chul Sung
Aug 15, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ronglin ZhaiWanli Zhang
Sep 6, 2014·Chinese Journal of Cancer·Elad SharonHelen X Chen
Oct 21, 2014·The Lancet Oncology·Sanjeet Bagcchi
Oct 26, 2014·Drugs·Kent ShihJeffrey R Infante
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jan 3, 2016·Cancer Letters·Kelly FoleyLei Zheng
Feb 21, 2016·Critical Reviews in Oncology/hematology·Sara GandiniMario Mandalà
May 4, 2016·Oncoimmunology·Tong Seng LimPaola Ricciardi-Castagnoli
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Nov 3, 2016·The New England Journal of Medicine·Vassiliki A Boussiotis
Nov 5, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Shingo InagumaMarkku Miettinen
Dec 3, 2016·Cancer Discovery·Daniel Sanghoon ShinAntoni Ribas
Dec 7, 2016·World Journal of Gastroenterology : WJG·Henrik JohanssonDaniel Ansari
Dec 16, 2016·Oncotarget·Yinan DongXinwei Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.